Adam Koppel Net Worth

The estimated Net Worth of Adam Koppel is at least $61.2 Milhão dollars as of 3 June 2021. Adam Koppel owns over 3,333 units of Dicerna Pharmaceuticals Inc stock worth over $127,387 and over the last 11 years he sold DRNA stock worth over $60,769,950. In addition, he makes $307,490 as Independent Director at Dicerna Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Adam Koppel DRNA stock SEC Form 4 insiders trading

Adam has made over 13 trades of the Dicerna Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 3,333 units of DRNA stock worth $127,387 on 3 June 2021.

The largest trade he's ever made was buying 3,333,333 units of Dicerna Pharmaceuticals Inc stock on 14 January 2020 worth over $9,999,999. On average, Adam trades about 133,819 units every 52 days since 2013. As of 3 June 2021 he still owns at least 3,333 units of Dicerna Pharmaceuticals Inc stock.

You can see the complete history of Adam Koppel stock trades at the bottom of the page.

Adam Koppel biography

Dr. Adam Koppel M.D., Ph.D. serves as Independent Director of the Company. Dr. Koppel rejoined Bain Capital in 2016 as a managing director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003 where he was a leader within the healthcare sector until mid-2014. During the period mid-2014 to mid-2016, Dr. Koppel worked at Biogen, Inc. (NASDAQ: BIIB) where he served as Executive Vice President of Corporate Development and Chief Strategy Officer. Prior to joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey & Co. in New Jersey, where he served a variety of healthcare companies. Dr. Koppel received an M.D. and Ph.D. in neuroscience from the University of Pennsylvania School of Medicine. He also received an M.B.A. from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an A.B. and A.M. in history and science. Dr. Koppel currently serves on the Board of Directors of Aptinyx Inc. (NASDAQ: APTX) and Solid Biosciences Inc. (NASDAQ: SLDB), and he previously served as a director of Trevena, Inc. (NASDAQ: TRVN) from September 2014 until October 2018 and PTC Therapeutics, Inc. from March 2013 until June 2017. The Nominating and Corporate Governance Committee believes that Dr. Koppel’s background as an executive officer, director, and venture capital investor in biopharmaceutical companies, as well as his scientific and medical background, provide him with the qualifications and skills to serve as a member of our Board of Directors.

What is the salary of Adam Koppel?

As the Independent Director of Dicerna Pharmaceuticals Inc, the total compensation of Adam Koppel at Dicerna Pharmaceuticals Inc is $307,490. There are 7 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of $5,048,130.

How old is Adam Koppel?

Adam Koppel is 50, he's been the Independent Director of Dicerna Pharmaceuticals Inc since 2017. There are 12 older and 1 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.

What's Adam Koppel's mailing address?

Adam's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE 700, CAMBRIDGE, MA, 02139.

Insiders trading at Dicerna Pharmaceuticals Inc

Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo, ePeter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.

What does Dicerna Pharmaceuticals Inc do?

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.

Complete history of Adam Koppel stock trades at Biogen Inc, Dicerna Pharmaceuticals Inc, PTC Therapeutics Inc, Trevena Inc, Solid Biosciences Inc, Aptinyx Inc, eFoghorn Therapeutics

Dicerna Pharmaceuticals Inc executives and stock owners

Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Douglas Fambrough,
  President, Chief Executive Officer, Director
• Robert Ciappenelli,
  Chief Commercial Officer
• Bob Brown,
  Executive Vice President, Research and Development, Chief Scientific Officer
• James Weissman,
  Chief Operating Officer, Executive Vice President
• J. Kevin Buchi,
  Independent Chairman of the Board
• Marc Kozin,
  Independent Director
• Anna Protopapas,
  Independent Director
• Adam Koppel,
  Independent Director
• Stephen Hoffman,
  Independent Director
• Martin Freed,
  Independent Director
• Cynthia Smith,
  Independent Director
• Patrick Gray,
  Independent Director
• Ling Zeng,
  Chief Legal Officer and Secretary
• Shreeram Aradhye,
  Executive Vice President, Chief Medical Officer
• Douglas Pagan,
  Chief Financial Officer
• Stephen Doberstein,
  Independent Director
• Capital Management, Llc Kol...,
  
• Partners Viii, L.P.Blair Ja...,
  
• Theodore Ashburn,
  See Remarks
• John B Green,
  Chief Financial Officer
• David Madden,
  Director
• Pankaj Bhargava,
  Chief Medical Officer
• Viii Associates, L.P.Blair ...,
  
• Bruce Peacock,
  Director
• Ralf Rosskamp,
  Chief Medical Officer
• Brian K Halak,
  Director
• Regina M. Paglia,
  Chief Human Resources Officer
• Capital Life Sciences Inves...,
  
• Capital Management, Llcra C...,
  
• Peter Kolchinsky,
  Director
• Bart W Wise,
  SVP, Legal Affairs
• Dennis Langer,
  Director
• James C Blair,
  10% owner
• Venture Partners V Lp Skyli...,
  
• James E Dentzer,
  Chief Financial Officer
• James E Deerfield Mgmt L.P....,
  
• James E Deerfield Mgmt L.P....,
  
• Vincent J Miles,
  Director
• Capital Management Llcbrook...,
  
• Kathleen K Schoemaker,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Nicole Vitullo,
  10% owner
• Brian H Dovey,
  10% owner
• Jesse I Treu,
  10% owner
• Viii Associates, L.P. Dp,
  10% owner
• Partners Viii, L.P. Domain,
  10% owner